Transcode Therapeutics Stock In The News

RNAZ Stock  USD 0.34  0.04  9.71%   
Our overall analysis of Transcode Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Transcode Therapeutics. The specific impact of Transcode Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Transcode Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Transcode Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Transcode Therapeutics Backtesting and Transcode Therapeutics Hype Analysis.
For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

Transcode Therapeutics Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
https://www.globenewswire.com/news-release/2023/11/14/2780566/0/en/TransCode-Therapeutics-Reports-Third-Quarter-2023-Results-Provides-Business-Update.html
 Neutral
Macroaxis News: globenewswire.com
TransCode Therapeutics Withdraws Public Offering
https://www.globenewswire.com/news-release/2023/10/30/2769725/0/en/TransCode-Therapeutics-Withdraws-Public-Offering.html
 Neutral
Macroaxis News: globenewswire.com
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
https://www.globenewswire.com/news-release/2023/10/27/2768349/0/en/Nasdaq-Panel-Grants-TransCode-Therapeutics-Extension-for-Continued-Listing-on-The-Nasdaq-Stock-Market-Subject-to-Conditions.html
 Neutral
Macroaxis News: globenewswire.com
TransCode Therapeutics Announces Public Offering of Common Stock
https://www.globenewswire.com/news-release/2023/10/26/2768034/0/en/TransCode-Therapeutics-Announces-Public-Offering-of-Common-Stock.html
 Neutral
Macroaxis News: globenewswire.com
TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
https://www.globenewswire.com/news-release/2023/10/26/2767453/0/en/TransCode-Therapeutics-Announces-Prolonged-Survival-in-Murine-Models-with-Glioblastoma-Treated-with-Its-Lead-Candidate-TTX-MC138.html
 Neutral
Macroaxis News: globenewswire.com
TransCode Therapeutics Announces Prelimi...
https://www.globenewswire.com/news-release/2023/10/24/2765543/0/en/TransCode-Therapeutics-Announces-Preliminary-Clinical-Results-in-First-Patient-in-Phase-0-Clinical-Study-with-Lead-Therapeutic-Candidate-TTX-MC138.html
 Neutral
Macroaxis News: globenewswire.com
TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA
https://www.globenewswire.com/news-release/2023/10/16/2760594/0/en/TransCode-Therapeutics-Reports-Successful-Treatment-of-Preclinical-Melanoma-Tumors-with-its-Immunotherapy-Candidate-TTX-RIGA.html
 Neutral
Macroaxis News: globenewswire.com
TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
https://www.globenewswire.com/news-release/2023/09/28/2751625/0/en/TransCode-Therapeutics-Announces-Closing-of-8-5-Million-Public-Offering.html
 Neutral
Macroaxis News: globenewswire.com
TransCode Therapeutics Announces Pricing of $8 Million Public Offering
https://www.globenewswire.com/news-release/2023/09/26/2749099/0/en/TransCode-Therapeutics-Announces-Pricing-of-8-Million-Public-Offering.html
 Neutral
Yahoo News
Amazon Invests Up To $4B In ChatGPT Comp...
https://finance.yahoo.com/news/amazon-invests-4b-chatgpt-competitor-165823564.html
 Bullish

Transcode Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Transcode and other traded companies coverage with news coverage. We help investors stay connected with Transcode headlines for the 28th of November to make an informed investment decision based on correlating the impacts of news items on Transcode Stock performance. Please note that trading solely based on the Transcode Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Transcode Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Transcode Therapeutics investors visualize upcoming and past events in order to time the market based on Transcode Therapeutics noise-free hype analysis.
Transcode Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Transcode earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Transcode Therapeutics that are available to investors today. That information is available publicly through Transcode media outlets and privately through word of mouth or via Transcode internal channels. However, regardless of the origin, that massive amount of Transcode data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Transcode Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Transcode Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Transcode Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Transcode Therapeutics alpha.

Transcode Largest EPS Surprises

Earnings surprises can significantly impact Transcode Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-05-16
2022-03-31-0.25-0.220.0312 
2022-08-15
2022-06-30-0.3-0.36-0.0620 
2022-11-14
2022-09-30-0.4-0.330.0717 
2023-11-13
2023-09-30-1.5-1.68-0.1812 
2024-11-18
2024-09-30-0.49-0.160.3367 
2024-08-16
2024-06-30-23.2-29.6-6.427 
View All Earnings Estimates

Transcode Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Transcode Therapeutics Stock. The global stock market is bearish. About 62% of major world exchanges and indexes are down. See today's market update for more information.
Investing News at Macroaxis
25th of November 2024
TransCode Therapeutics advances with stockholder approvals
at investing.com 
Google News at Macroaxis
15th of November 2024
TransCode Therapeutics Inc Quarterly 10-Q Report - Quartzy
at news.google.com 
Yahoo News
23rd of October 2024
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening...
at finance.yahoo.com 
Yahoo News
10th of September 2024
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Reve...
at finance.yahoo.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Transcode Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Transcode Therapeutics' short interest history, or implied volatility extrapolated from Transcode Therapeutics options trading.

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.